Search
46 studies match these filters. Showing 1–25 of 46 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT07136012 | OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]). ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 261 sites in total | Recruiting | Phase 3 | 11,000target | 261 / 4 | 2025 | Nov 16, 2026 | |
| NCT07543120 | An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 46 sites in total · contact listed | Recruiting | Phase 2 | 323target | 46 / 3 | 2026 | Nov 16, 2026 | |
| NCT07321899 | Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 20 sites in total · contact listed | Recruiting | Not applicable | 1,186target | 20 / 1 | 2026 | Nov 12, 2026 | |
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adju… ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 1,226 sites in total | Recruiting | Phase 3 | 11,000target | 1,226 / 35 | 2025 | Nov 12, 2026 | |
| NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empag… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 672 sites in total · contact listed | Recruiting | Phase 3 | 6,712target | 672 / 30 | 2024 | Nov 12, 2026 | |
| NCT06935370 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find out… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 596 sites in total · contact listed | Recruiting | Phase 3 | 4,200target | 596 / 29 | 2025 | Nov 12, 2026 | |
| NCT07516444 | VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial) Pivotal trial to evaluate the safety and clinical efficacy of the VDyne TriNova System for the treatment of symptomatic severe or greater tricuspid regurgitation. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 12 sites in total · contact listed | Recruiting | Not applicable | 520target | 12 / 1 | 2026 | Nov 10, 2026 | |
| NCT07045194 | Virtue® SAB in the Treatment of Coronary ISR Trial A prospective, multi-center, single-blind, randomized (1:1), non-inferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the treatment of coronary artery in-stent restenosis (ISR). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 22 sites in total · contact listed | Recruiting | Not applicable | 740target | 22 / 1 | 2025 | Oct 22, 2026 | |
| NCT06677060 | Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 977 sites in total | Recruiting | Phase 3 | 11,300target | 977 / 35 | 2025 | Oct 21, 2026 | |
| NCT05913908 | EFS of the DUO System for Tricuspid Regurgitation The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 18 sites in total · contact listed | Recruiting | Not applicable | 15target | 18 / 2 | 2024 | Oct 21, 2026 | |
| NCT06535854 | Prevail Global Study The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 79 sites in total · contact listed | Recruiting | Not applicable | 1,205target | 79 / 9 | 2025 | Oct 21, 2026 | |
| NCT07830719 | Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by eleva… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 23 sites in total · contact listed | Recruiting | Phase 2 | 180target | 23 / 5 | 2026 | Oct 15, 2026 | |
| NCT06777368 | REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 71 sites in total · contact listed | Recruiting | 225target | 71 / 1 | 2025 | Sep 24, 2026 | ||
| NCT06033274 | Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment The field of transcatheter tricuspid valve replacement (TTVR) is rapidly emerging and data on this topic are scarce. Particularly, little is known about which patients are at greatest risk of procedural complications, such as the timing and onset of conduction disturbances necessitating permanent pa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 31 sites in total | Recruiting | 800target | 31 / 8 | 2023 | Sep 15, 2026 | ||
| NCT07761117 | A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF),… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 679 sites in total | Recruiting | Phase 3 | 6,950target | 679 / 32 | 2026 | Sep 28, 2026 | |
| NCT05172960 | ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 65 sites in total | Recruiting | Not applicable | 1,234target | 65 / 4 | 2022 | Sep 24, 2026 | |
| NCT07000357 | A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs pl… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 1,452 sites in total | Recruiting | Phase 3 | 15,100target | 1,452 / 36 | 2025 | Aug 24, 2026 | |
| NCT05712200 | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy. ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 789 sites in total · contact listed | Recruiting | Phase 3 | 2,500target | 789 / 35 | 2022 | Jul 13, 2026 | |
| NCT05378347 | Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Excluder / Excluder Conformable AAA Endoprosthesis in subjects with Abdominal Aortic Aneurysms. Subjects are randomized and imaging collected at all follo… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 68 sites in total · contact listed | Recruiting | Not applicable | 600target | 68 / 12 | 2023 | Jul 6, 2026 | |
| NCT05172973 | ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 37 sites in total | Recruiting | Not applicable | 200target | 37 / 2 | 2023 | Oct 7, 2026 | |
| NCT06438315 | SuperSaturated Oxygen Comprehensive Observational Registry The SuperSaturated Oxygen Comprehensive Observational Registry (SSCORE) registry, a prospectively designed observational study, aims to evaluate the clinical utility, infarct size reduction, and cost-effectiveness of SSO2 Therapy versus PCI alone among patients with anterior AMI in routine clinical practice. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 27 sites in total · contact listed | Recruiting | 1,000target | 27 / 1 | 2024 | Nov 2, 2026 | ||
| NCT06779630 | Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel d… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 23 sites in total | Recruiting | Not applicable | 150target | 23 / 6 | 2025 | Nov 5, 2026 | |
| NCT07090161 | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 28 sites in total | Recruiting | Phase 2 | 240target | 28 / 1 | 2025 | Feb 27, 2026 | |
| NCT05061004 | Cephea Early Feasibility Study The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 22 sites in total · contact listed | Recruiting | Not applicable | 90target | 22 / 2 | 2022 | Sep 11, 2026 | |
| NCT04889872 | PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 80 sites in total | Recruiting | Not applicable | 2,250target | 80 / 6 | 2021 | Dec 17, 2025 |